Manila:Thailand is facing a significant challenge with the increasing prevalence of type 2 diabetes, which is projected to rise from 9.5% in 2020 to 10.6% in 2025. Current treatment strategies are evolving from solely controlling blood sugar levels to a more comprehensive approach aimed at preventing serious comorbidities.
According to Thai News Agency, Novo Nordisk Pharma (Thailand) Co., Ltd. is highlighting the connection between heart, kidney, and metabolic syndrome (CKM Syndrome) and is committed to supporting those living with type 2 diabetes in Thailand. The company is also enhancing public awareness of this chronic disease by introducing high-dose semaglutide treatment, thereby expanding options for healthcare providers and patients.
Medical science indicates that type 2 diabetes is a progressive disease associated with CKM syndrome, affecting critical systems. In the cardiovascular system, coronary heart disease, heart failure, and stroke are leading causes of death for these patients. For the renal system, chronic kidney disease affects up to 40% of patients, with diabetes being the primary cause of end-stage renal failure in Thailand. The metabolic system is also impacted, with obesity as a common contributing factor, increasing the risk of severe metabolic disorders.
Pharmaceutical research has led to innovative treatments within the semaglutide molecular group, providing higher-dose options that significantly aid in managing type 2 diabetes. These treatments not only control blood sugar but also contribute to weight loss and reduced CKM comorbidities, offering substantial benefits for long-term care.
At a recent medical conference, experts emphasized the importance of effective communication between doctors and patients. Patients with type 2 diabetes are encouraged to engage in comprehensive treatment planning with specialists, beyond just monitoring blood sugar levels. Assessing cardiovascular and renal risks simultaneously allows for personalized treatment plans, reducing future healthcare burdens and enhancing patients' quality of life.